Loading Events

Cardio Connections: Heart Failure & AFib

October 24, 2024

9:00 am CDT -12:30 pm CDT

Join us for Cardio Connections: Heart Failure & AFib, a virtual event where national thought leaders discuss guideline-directed medical therapy for atrial fibrillation and worsening heart failure. Dr. Tara Whitmire, Immediate Past President of the American Association of Heart Failure Nurses, will provide insights on screening, assessment, and practical application of guidelines through case studies. Discover innovative treatment approaches, the impact of social determinants of health, and the crucial role of cardiovascular nurses in patient management and education.

Earn 1.5 CE contact hours, including 1.5 pharmacology, when you join us in a deep dive into heart failure.

You can join the summit at this link.

Agenda

9:00 AM CTWelcome
9:15 AM CTSpotlight on Worsening Heart Failure (0.75 CE, including 0.75 pharmacology CE)
Tara Whitemire DNP, APRN-NP, CHFN, ACUE
10:00 AM CTDisease State Theater hosted by Novartis Pharmaceuticals
Finding Lp(a): Why the “little” Things Matter
10:45 AM CTBreak
11:00 AM CTAtrial Fibrillation GDMT: Implementing the latest guidelines (0.75 CE, including 0.75 pharmacology CE)
Jackson Hermanson PA-C, MS
11:45 AM CTProduct Theater hosted by the BMS-Pfizer Alliance
Let's Get to the Heart of it: Explore how evidence generation and select methodological approaches can help inform clinical practice in patients with nonvalvular atrial fibrillation (NVAF)
12:30 PM CTClosing

Learning Objectives

Spotlight on Worsening Heart Failure (.75 CE/.75 Pharm CE)

  • Review heart failure (HF) guideline-directed medical therapy (GDMT)
  • Discuss screening and assessment for worsening HF despite GDMT
  • Explore a case study of a patient receiving novel therapeutic agents in patients with progression of HFrEF despite GDMT

Atrial Fibrillation GDMT: Implementing the latest guidelines (.75 CE/.75 Pharm CE)

  • Review of the 2023 Guideline for the Diagnosis and Management of Atrial Fibrillation
  • Examine the benefits of early rhythm control and the impact of social determinants of health on diagnosis, management, and treatment of AFib
  • Discuss pharmacological and non-pharmacological treatment approaches for rate and rhythm control of Afib, embolism, and stroke

 

Thank you to Merck Sharpe & Dohme Corporation, the Bristol Myers Squibb-Pfizer Alliance, and Novartis Pharmaceuticals for their support of this program.